on-interventional study for recording the treatment and the influence on the treatment-specific quality of life with patients with hormone-refractory prostate cancer under a Docetaxel (Eurotere®) containing chemotherapy.
Recruiting
- Conditions
- Hormone Refractory Prostate CancerC61Malignant neoplasm of prostate
- Registration Number
- DRKS00003069
- Lead Sponsor
- apharm GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 500
Inclusion Criteria
Histologically confirmed hormone-refractory prostate cancer.
Signed patient informed consent form.
Exclusion Criteria
Other malignant diseases in the past 5 years,
Lack of compliance.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life by means of the validated Patient Oriented Prostate Cancer Utility Scale (PORPUS) at the beginning of the observation, after 3 months and after 9 months.<br>
- Secondary Outcome Measures
Name Time Method Impact of the form of the therapy (mono, combination, application frequency) on the course of the therapy,<br>Impact of prior symptoms on the course of the therapy,<br>Predictive criteria for an improvement of the quality of life,<br>Collection of prognostic criteria,<br>Association between tumor response and treatment specific quality of life,<br>Evaluation of adverse drug reactions / events.<br>